# Margaret K. Callahan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/margaret-k-callahan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 51,616 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 69 |
| i10-index | 152 |
| Last Known Institution | University of Connecticut |
| OpenAlex ID | https://openalex.org/A5011114578 |
| ORCID iD | https://orcid.org/0000-0002-9087-0012 |
| Works | 429 |

## Researcher papers

- [OncoKB: A Precision Oncology Knowledge Base](https://scholariq.org/papers/oncokb-a-precision-oncology-knowledge-base/)
- [Immune-related adverse events of checkpoint inhibitors](https://scholariq.org/papers/immune-related-adverse-events-of-checkpoint-inhibitors/)
- [Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy](https://scholariq.org/papers/pneumonitis-in-patients-treated-with-anti-programmed-death-1-programmed-death/)
- [Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/genomic-features-of-response-to-combination-immunotherapy-in-patients-with/)
- [Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas](https://scholariq.org/papers/relief-of-profound-feedback-inhibition-of-mitogenic-signaling-by-raf-inhibitors/)
- [Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution](https://scholariq.org/papers/endocrine-related-adverse-events-following-ipilimumab-in-patients-with-advanced/)
- [Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort](https://scholariq.org/papers/nivolumab-monotherapy-and-nivolumab-plus-ipilimumab-in-recurrent-small-cell-lung/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

## Researcher university

- [University of Connecticut](https://scholariq.org/institutions/university-of-connecticut/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.